Time：4:00-5:30 PM，Tuesday, January 9, 2024

    Host：Dr. Duanqing Pei, Chair Professor of School of Life Sciences

    Venue：E9-109, Yungu Campus

Speaker:

Dr. Guideng Li, Principal Investigator, Institute of Systems Medicine, Chinese Academy of Medical Sciences, Suzhou Institute of Systems Medicine

Dr. Guideng Li completed his bachelor's and master's degrees at Xiamen University before earning his Ph.D. in immunology from the University of California, Irvine, in 2012. Following this, he conducted postdoctoral research at the California Institute of Technology (Caltech) under the mentorship of Nobel Laureate David Baltimore. Dr. Guideng Li undertook the role of Principal Investigator at the Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences in 2019, where he currently leads the Laboratory of Engineering Immunity. His laboratory aims to decipher the molecular mechanisms responsible for productive or defective immune responses against chronic diseases and exploit this knowledge to design effective therapeutic strategies with potential clinical applications.  His ongoing research centers on T-cell antigen recognition, the regulation of T-cell function and differentiation, and TCR-T cell immunotherapy. He has published several corresponding author papers in highly prestigious journals, such as Nature Metabolism (2023 cover story), Nature Methods (2019,2020,2022), Nature Reviews Immunology (2019), Nature Communications (2020) and Blood (2019).

Abstract:

T cells stand out as pivotal immune cells within the body's immune system. Activated and differentiated T cells recognize a diverse range of antigens through the T-cell receptor, empowering them to eliminate foreign antigens and combat tumor cells. Despite the wealth of T-cell receptor (TCR) information derived from single-cell sequencing technology in healthy individuals, those with infectious diseases, and cancer patients, the scarcity of TCR-antigen pairings significantly hampers the practical application of TCR-T therapy in the clinical treatment of solid tumors.  Over the recent years, we have developed diverse platforms aimed at identifying and screening targets for TCR antigens. This has enabled us to unravel the antigenic epitopes acknowledged by TCRs originating from both cancer patients and individuals affected by COVID-19.  Additionally, our investigations have delved into comprehending the influence of the acidic microenvironment within tumors on the differentiation of antigen-specific T cells.

Contact：

Wenyue Yu: yuwenyue@westlake.edu.cn

School of Life Sciences